Clinical Trial

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-13; most recent amendment 2024-09-29.
Trial Details
NCT Number NCT06418477
Lead Sponsor Peking University People's Hospital
Conditions Monoclonal Gammopathy of Renal Significance
Enrollment 20 participants
Start Date 2024-06-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01